17 June 2020
Clearside Biomedical , Inc. (Nasdaq:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple oral presentations on Clearside’s pipeline and its proprietary SCS Microinjector® targeting the suprachoroidal space (SCS®) are available online at the ARVO 2020 Meeting.
16 June 2020
binx health today announced the first of its kind private offering for at-home sample collection and contactless courier service for laboratory COVID-19 testing for all residents in the United Kingdom. Leveraging the binx digital platform and the Company's decade of experience developing evidence-based, near-patient infectious disease diagnostics, binx and Polar Speed, a specialist UPS Healthcare business in the UK, have partnered together to broaden access to testing for patients where they need it most—from the comfort and security of their own homes.
15 June 2020
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat orphan seizure disorders, today announced that Martha Manning, Esq., has been appointed Vice President, General Counsel and Secretary.
02 June 2020
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the closing of an underwritten public offering of 18,400,000 shares of common stock at a public offering price of $2.50 per share, including the exercise in full by the underwriters of their option to purchase up to 2,400,000 additional shares of common stock. The offering raised gross proceeds of approximately $46 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.
26 May 2020
Epic Sciences, Inc. today announced that it will present three abstracts at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program to be held from May 29 – June 2, 2020. Epic Sciences will present new data demonstrating the role of circulating tumor cells (CTCs) in cancer prognosis and treatment outcomes.
21 May 2020
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced receipt of the final results of E2112, the Phase 3 clinical trial conducted by ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and sponsored by the National Cancer Institute (NCI), that evaluated the investigational compound entinostat, Syndax's class I HDAC inhibitor, plus exemestane in patients with advanced hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) breast cancer who have progressed on a non-steroidal aromatase inhibitor. The trial did not achieve the primary endpoint of demonstrating a statistically significant overall survival (OS) benefit over hormone therapy alone.
20 May 2020
Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections, today announced a $215 million Series D financing. The financing was led by Bain Capital Life Sciences and also included new investors RA Capital Management, Perceptive Advisors, Rock Springs Capital, Adage Capital Management, funds and accounts managed by T. Rowe Price Associates, Inc., Redmile Group, and Omega Funds. Existing Atea investors, including Morningside Ventures, Cormorant Asset Management, Ally Bridge Group, and Sectoral Asset Management, as well as other investors also participated in this financing.
14 May 2020
binx health today announced the publication of its pivotal clinical study for its rapid molecular point-of-care platform, the binx io, in The Journal of the American Medical Association (JAMA) Network Open. The study shows that the binx io provides accurate results in about 30 minutes, enabling single visit test and treatment for chlamydia (CT) and gonorrhea (NG), two of the most tested-for sexually transmitted infections (STIs) globally. binx received FDA 510(k) clearance for its CT/NG Assay in August 2019 for female swabs and in April 2020 for male urine samples. The standard of care today for CT/NG testing often requires 2-10 days of delay between sample collection and answer, resulting up to 40% of positive patients not returning for treatment.
05 May 2020
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended March 31, 2020 . In addition, the Company provided a clinical and business update.
05 May 2020
Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the first quarter ended March 31, 2020 .
03 July 2020
03 July 2020
02 July 2020
02 July 2020